Literature DB >> 11801334

Alzheimer's disease-do tauists and baptists finally shake hands?

Amritpal Mudher1, Simon Lovestone.   

Abstract

The amyloid cascade hypothesis has been the predominant model of molecular pathogenesis in Alzheimer's disease. The finding of tau mutations in other dementias has added weight to the hypothesis as it suggests that tau-pathology is a downstream but essential part of the dementing process. However, some observations remain difficult to reconcile with the hypothesis. In transgenic mice, for example, amyloid generation does not induce the predicted cascade and in man, plaques and tangles are separated temporally and spatially. One alternative possibility is that some common factor, loss of wnt signalling for example, might induce both plaques and tangles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801334     DOI: 10.1016/s0166-2236(00)02031-2

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  137 in total

1.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

2.  The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer's disease.

Authors:  Ai-Wu Xiao; Jing He; Qian Wang; Yi Luo; Yan Sun; Yan-Ping Zhou; Yang Guan; Paul J Lucassen; Jia-Pei Dai
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 3.  Prevention of Alzheimer's disease: where we stand.

Authors:  Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

4.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

5.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

Review 6.  Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease.

Authors:  Federico Cacciapuoti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

Review 7.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

Review 8.  A common biological mechanism in cancer and Alzheimer's disease?

Authors:  M I Behrens; C Lendon; C M Roe
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

9.  β-Amyloid (1-40) peptide interactions with supported phospholipid membranes: a single-molecule study.

Authors:  Hao Ding; Joseph A Schauerte; Duncan G Steel; Ari Gafni
Journal:  Biophys J       Date:  2012-10-02       Impact factor: 4.033

Review 10.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.